Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics.

Nielly H, Mathian A, Cazenave M, Izzedine H, Haroche J, Cohen-Aubart F, Hie M, Miyara M, Pineton de Chambrun M, Benameur N, Hausfater P, Pha M, Boutin-Lê Thi Huong D, Rouvier P, Brocheriou I, Cluzel P, Amoura Z.

Nephrol Dial Transplant. 2019 Jun 3. pii: gfz085. doi: 10.1093/ndt/gfz085. [Epub ahead of print]

PMID:
31157889
2.

Renal toxicities associated with pembrolizumab.

Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, Varga A, Malka D, Leary A, Michels J, Michot JM, Marabelle A, Lambotte O, Amoura Z, Soria JC, Kaaki S, Quellard N, Goujon JM, Brocheriou I.

Clin Kidney J. 2019 Feb;12(1):81-88. doi: 10.1093/ckj/sfy100. Epub 2018 Nov 9.

3.

[Drug nephrotoxicity].

Izzedine H.

Nephrol Ther. 2018 May;14(3):127-134. doi: 10.1016/j.nephro.2017.06.006. Epub 2018 Mar 11. Review. French.

PMID:
29540291
4.

Anticancer Drug-Induced Acute Kidney Injury.

Izzedine H, Perazella MA.

Kidney Int Rep. 2017 Feb 16;2(4):504-514. doi: 10.1016/j.ekir.2017.02.008. eCollection 2017 Jul. Review.

5.

[Thrombotic microangiopathy and cancer].

Kheder El-Fekih R, Deltombe C, Izzedine H.

Nephrol Ther. 2017 Nov;13(6):439-447. doi: 10.1016/j.nephro.2017.01.023. Epub 2017 Jul 31. Review. French.

PMID:
28774729
6.

Adverse kidney effects of epidermal growth factor receptor inhibitors.

Izzedine H, Perazella MA.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1089-1097. doi: 10.1093/ndt/gfw467. Review.

PMID:
28339780
7.

Renal effects of immune checkpoint inhibitors.

Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A.

Nephrol Dial Transplant. 2017 Jun 1;32(6):936-942. doi: 10.1093/ndt/gfw382. Review.

PMID:
28025384
8.

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Boissier E, Mir O, Hollebecque A, Izzedine H, Ederhy S, Gazzah A, Bahleda R, Massard C, Macquin-Mavier I, Tournigand C, Spano JP, Soria JC, Rousseau B.

Invest New Drugs. 2017 Feb;35(1):79-86. doi: 10.1007/s10637-016-0402-3. Epub 2016 Oct 25.

PMID:
27783256
9.

Panitumumab-Induced Immune Complex Glomerulonephritis.

Izzedine H, Boostandoost H, Mathian A.

Am J Kidney Dis. 2017 Feb;69(2):320-321. doi: 10.1053/j.ajkd.2016.09.011. Epub 2016 Oct 17. No abstract available.

PMID:
27765383
10.

The renal effects of ALK inhibitors.

Izzedine H, El-Fekih RK, Perazella MA.

Invest New Drugs. 2016 Oct;34(5):643-9. doi: 10.1007/s10637-016-0379-y. Epub 2016 Jul 29. Review.

PMID:
27468827
11.

Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study.

Berdelou A, Boige V, Arfi-Rouche J, Malka D, Ederhy S, Izzedine H, Leboulleux S, Chougnet CN, Burtin P, De Baere T, Laplanche A, Elias D, Schlumberger M, Scoazec JY, Ducreux M, Baudin E.

Neuroendocrinology. 2017;105(1):26-34. doi: 10.1159/000446988. Epub 2016 May 26.

12.

[Lenalidomide nephrotoxicity].

Kheder El-Fekih R, Izzedine H.

Bull Cancer. 2016 May;103(5):499-506. doi: 10.1016/j.bulcan.2016.01.020. Epub 2016 Feb 28. Review. French.

PMID:
26927826
13.

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.

Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA.

Oncology. 2016;90(1):10-20. doi: 10.1159/000440958. Epub 2015 Oct 23.

PMID:
26492090
14.

The Authors Reply.

Perazella MA, Izzedine H.

Kidney Int. 2015 Jul;88(1):200. doi: 10.1038/ki.2015.135. No abstract available.

PMID:
26126103
15.

Thrombotic microangiopathy, cancer, and cancer drugs.

Izzedine H, Perazella MA.

Am J Kidney Dis. 2015 Nov;66(5):857-68. doi: 10.1053/j.ajkd.2015.02.340. Epub 2015 May 2. Review.

PMID:
25943718
16.

Mutation Update of the CLCN5 Gene Responsible for Dent Disease 1.

Mansour-Hendili L, Blanchard A, Le Pottier N, Roncelin I, Lourdel S, Treard C, González W, Vergara-Jaque A, Morin G, Colin E, Holder-Espinasse M, Bacchetta J, Baudouin V, Benoit S, Bérard E, Bourdat-Michel G, Bouchireb K, Burtey S, Cailliez M, Cardon G, Cartery C, Champion G, Chauveau D, Cochat P, Dahan K, De la Faille R, Debray FG, Dehoux L, Deschenes G, Desport E, Devuyst O, Dieguez S, Emma F, Fischbach M, Fouque D, Fourcade J, François H, Gilbert-Dussardier B, Hannedouche T, Houillier P, Izzedine H, Janner M, Karras A, Knebelmann B, Lavocat MP, Lemoine S, Leroy V, Loirat C, Macher MA, Martin-Coignard D, Morin D, Niaudet P, Nivet H, Nobili F, Novo R, Faivre L, Rigothier C, Roussey-Kesler G, Salomon R, Schleich A, Sellier-Leclerc AL, Soulami K, Tiple A, Ulinski T, Vanhille P, Van Regemorter N, Jeunemaître X, Vargas-Poussou R.

Hum Mutat. 2015 Aug;36(8):743-52. doi: 10.1002/humu.22804. Epub 2015 Jun 11. Review.

PMID:
25907713
17.

Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs).

Gharbi C, Gueutin V, Izzedine H.

Clin Kidney J. 2014 Apr;7(2):115-20. doi: 10.1093/ckj/sfu001. Epub 2014 Feb 24. Review.

18.

New drug toxicities in the onco-nephrology world.

Perazella MA, Izzedine H.

Kidney Int. 2015 May;87(5):909-17. doi: 10.1038/ki.2015.30. Epub 2015 Feb 11. Review.

PMID:
25671763
19.

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

Izzedine H, Perazella MA.

Nephrol Dial Transplant. 2015 Dec;30(12):1979-88. doi: 10.1093/ndt/gfu387. Epub 2015 Feb 3. Review.

20.

[Pemetrexed nephrotoxicity].

Izzedine H.

Bull Cancer. 2015 Feb;102(2):190-7. doi: 10.1016/j.bulcan.2014.12.012. Epub 2015 Jan 29. Review. French.

PMID:
25641712

Supplemental Content

Loading ...
Support Center